is missing (Short communication).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137361PMC
http://dx.doi.org/10.2340/00015555-3481DOI Listing

Publication Analysis

Top Keywords

unexpected hair
4
hair regrowth
4
regrowth patient
4
patient longstanding
4
longstanding alopecia
4
alopecia universalis
4
universalis treatment
4
treatment recalcitrant
4
recalcitrant dermatomyositis
4
dermatomyositis janus
4

Similar Publications

While most forms of alopecia neoplastica are attributable to cutaneous metastases from visceral primary malignancies, rarely a diffuse primary skin cancer may present as alopecia. Herein, we present a case of angiosarcoma which clinically mimicked an inflammatory alopecia and was diagnosed by examination of alopecia-protocol horizontal histologic sections. A 72-year-old female presented to her dermatologist with a chief complaint of hair loss and pruritus.

View Article and Find Full Text PDF

Investigation of the oxidation pathway of 5,6-dihydroxyindole (DHI), one of the main biosynthetic precursors of the brown-to-black skin and hair melanin pigments, represents a promising approach for the elucidation of the structure of these pigments in biological systems. We report herein the exploration of DHI oxidation chemistry under conditions so far poorly investigated, i.e.

View Article and Find Full Text PDF
Article Synopsis
  • - A 25-year-old woman with type II diabetes experienced severe nausea and vomiting, along with significant weight loss over 5 weeks, despite normal vital signs and extensive gastrointestinal testing.
  • - Further investigation revealed panhypopituitarism, a rare condition causing deficiencies in multiple pituitary hormones, particularly adrenocorticotropic hormone and cortisol, which were linked to her symptoms.
  • - After starting treatment for panhypopituitarism, her symptoms resolved within 24 hours, underscoring the importance of thorough medical history and examination in diagnosing rare conditions.
View Article and Find Full Text PDF

Real-world safety profile of zanubrutinib: a disproportionality analysis based on the FAERS database.

BMJ Open

October 2024

Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China

Article Synopsis
  • Zanubrutinib, a second-generation Bruton's tyrosine kinase inhibitor, is being studied for its adverse effects based on real-world data from the FDA’s AE Reporting System between 2019-2023.
  • A comprehensive analysis identified 846 AE reports related to zanubrutinib, revealing 74 positive signals across various organ systems, with key issues in blood disorders and significant signals like 'haemorrhage subcutaneous'.
  • The study indicates that switching from monotherapy to combination therapy with rituximab or chemotherapy escalates the risk of serious adverse events, with some unexpected off-label AEs also noted, such as skin discoloration and cardiac arrest.
View Article and Find Full Text PDF
Article Synopsis
  • * A case study details a 77-year-old woman with essential thrombocytosis who, after 20 weeks on low-dose hydroxyurea, experienced an unexpected change in hair color from gray to dark brown, along with other skin changes.
  • * The patient's side effect was monitored without intervention since she was pleased with the new hair color, suggesting that hydroxyurea may have both therapeutic benefits and unexpected aesthetic effects due to melanocyte activation.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!